about
Systematic Review of Inhaled Bronchodilator and Corticosteroid Therapies in Infants with Bronchopulmonary Dysplasia: Implications and Future DirectionsUtilization of inhaled corticosteroids for infants with bronchopulmonary dysplasiaTransient effects of transfusion and feeding advances (volumetric and caloric) on necrotizing enterocolitis development: A case-crossover studyPractice Variance, Prevalence, and Economic Burden of Premature Infants Diagnosed With GERD.Inhaled bronchodilator use for infants with bronchopulmonary dysplasia.Hospital variation in nitric oxide use for premature infants.Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasiaNeonatal Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Treatment at United States Children's HospitalsEffect of nasal noninvasive respiratory support methods on pharyngeal provocation-induced aerodigestive reflexes in infants.Pharmacological treatment of neonatal seizures: a systematic review.Nonsteroidal anti-inflammatory administration and patent ductus arteriosus ligation, a survey of practice preferences at US children's hospitals.False-negative results of pre-discharge neonatal bilirubin screening to predict severe hyperbilirubinemia: a need for caution.Vitamin D status of early preterm infants and the effects of vitamin D intake during hospital stay.Echocardiographic detection of pulmonary hypertension in extremely low birth weight infants with bronchopulmonary dysplasia requiring prolonged positive pressure ventilation.Sildenafil Treatment of Infants With Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension.Comparative Effectiveness of Nonsteroidal Anti-inflammatory Drug Treatment vs No Treatment for Patent Ductus Arteriosus in Preterm Infants.Feeding Methods at Discharge Predict Long-Term Feeding and Neurodevelopmental Outcomes in Preterm Infants Referred for Gastrostomy Evaluation.The effects of gestational age and birth weight on false-positive newborn-screening rates.Thyroid Function in the Neonatal Intensive Care Unit.Patterns of Empiric Antibiotic Administration for Presumed Early-Onset Neonatal Sepsis in Neonatal Intensive Care Units in the United States.In-frame de novo mutation in in two patients with muscular atrophy and arthrogryposisUtilization of blood spot testing for metabolic-genetic disorders in Honduras: is it time for newborn screening?Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG)Neurodevelopmental Outcome in Relation to Treatment of Patent Ductus ArteriosusCatheter-based closure of the patent ductus arteriosus in lower weight infantsTiming of postnatal steroids for bronchopulmonary dysplasia: association with pulmonary and neurodevelopmental outcomesCatheter-based closure of the patent ductus arteriosus in preterm infants: considerations in the design of a randomized trialEarly prediction of spontaneous Patent Ductus Arteriosus (PDA) closure and PDA-associated outcomes: a prospective cohort investigationReduction of Analgesia Duration after Tracheostomy during Neonatal Intensive Care: A Quality InitiativeFollow-up after Percutaneous Patent Ductus Arteriosus Occlusion in Lower Weight InfantsPercutaneous closure of the patent ductus arteriosus: opportunities moving forwardShining a Light on Concerns about Phototherapy to Prevent Allergic Skin DiseaseGabapentin Use for Hospitalized NeonatesPercutaneous Closure of the Patent Ductus Arteriosus in Very Low Weight Infants: Considerations Following US Food and Drug Administration Approval of a Novel Device
P50
Q26769743-5F915562-4CC2-4780-BB4B-8F8BED30BEA1Q28542831-7E46E719-D6A2-4310-AE70-A95B82A32AD5Q33817508-026E42F4-D0DA-4D81-A722-116D95F6A84FQ33823747-92D1FD92-6AFB-4FC9-99B4-1BA96B3E2CD8Q34797709-60F7E53A-055B-411C-92FC-10BE3346435EQ35855762-22708E22-2C9C-43F1-B4DB-94606903E5BAQ36717315-CE071A45-3D02-403D-9AC9-7608D1BF6A87Q37047798-6B3047BC-48BA-4664-9652-67EA0465AD39Q37071793-C0A3F29D-A7A1-4EF0-9809-5E9BC373270CQ37249019-EBF39589-B109-48DC-B4B0-FA4C85F85D5CQ37324451-79818D6F-3CD9-4722-B2B1-8061224EEE61Q37405244-A4C02C42-F975-41E9-9BDA-5D9E4BD51919Q37600325-C1512C22-9A00-484D-8F42-DAD13BD29C52Q37839700-49CE5BFB-25F9-4540-9A02-550B5B20DA06Q40213242-2C30F059-9B76-4F21-9EE6-C3FC654ACCA2Q40398107-83983FE7-9308-4F3B-9D70-5ECF1DB86342Q40431453-75DF8F51-7E1C-47B9-BA70-B1DF17D088FBQ42848217-863DA39A-C92C-4FEF-A36A-4118EDA400D8Q50186137-1E1146EB-FADC-4F2B-86A5-DA8238E6553CQ53645115-32894A88-871F-40AE-9712-4AF347FA4162Q58792934-8997648F-26DB-4899-9E61-1511DD1FF450Q84769205-96FBEA49-7E06-4942-AA9A-E01968F1383FQ88588805-8B871D1A-AFB1-43E6-AAF2-EF8E05EFD7EFQ88860428-8B21B437-A1DA-4EEB-AC55-6F838716C0E3Q89125637-3E0FCC6D-884B-4336-8D0D-225C4AB3ED5FQ89532691-99993986-2224-4A59-A7DA-C8497F948CB6Q90084070-E524D350-9FE5-4690-BCDF-B54D5292D2B4Q90098359-958F7B89-1EB6-4958-86A5-33B3FEC12329Q90747598-4B0219EF-B019-423A-ACB4-475AEA0248BDQ91524261-DC1E1CD6-A3EE-4491-8C0F-D190EDFD42C4Q91967066-F2B0F904-102B-4D91-AF1D-D5555D485759Q92481467-486E4BA2-3D6F-44B2-A619-FE96E085E118Q92684407-7D9E8C86-850D-4F33-A139-FDF86C31B5AEQ93127298-E77ECC59-2DAD-4581-B06E-CA95C2D3CD3E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jonathan Slaughter
@ast
Jonathan Slaughter
@en
Jonathan Slaughter
@es
Jonathan Slaughter
@nl
Jonathan Slaughter
@sl
type
label
Jonathan Slaughter
@ast
Jonathan Slaughter
@en
Jonathan Slaughter
@es
Jonathan Slaughter
@nl
Jonathan Slaughter
@sl
prefLabel
Jonathan Slaughter
@ast
Jonathan Slaughter
@en
Jonathan Slaughter
@es
Jonathan Slaughter
@nl
Jonathan Slaughter
@sl
P108
P1053
E-4102-2011
P106
P108
P1153
35226718500
P21
P31
P3829
P496
0000-0001-6831-7520